About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Slc40a1tm2Nca
targeted mutation 2, Nancy C Andrews
MGI:3771548
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Meox2tm1(cre)Sor/Meox2+
Slc40a1tm2Nca/Slc40a1tm2Nca
involves: 129S4/SvJae * 129S6/SvEvTac MGI:3771551
cn2
Slc40a1tm2Nca/Slc40a1tm2Nca
Tg(Vil-cre)20Syr/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2 MGI:3771552
cn3
Slc40a1tm2Nca/Slc40a1tm2Nca
Tg(Vil-cre/ERT2)23Syr/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2 MGI:3771553


Genotype
MGI:3771551
cn1
Allelic
Composition
Meox2tm1(cre)Sor/Meox2+
Slc40a1tm2Nca/Slc40a1tm2Nca
Genetic
Background
involves: 129S4/SvJae * 129S6/SvEvTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Meox2tm1(cre)Sor mutation (2 available); any Meox2 mutation (9 available)
Slc40a1tm2Nca mutation (1 available); any Slc40a1 mutation (17 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• unlike homozygous null mice, mice with conditional deletion in embryonic tissues that retain expression in the extraembryonic visceral endoderm and in the placenta survive past birth

hematopoietic system
• severe iron deficient anemia
• at 18 - 22 days of age
• hypochromic at P10
• reduced in both mature erythrocytes and reticulocytes at 18 - 22 days of age
• at 18 - 22 days of age
• at P10
• at P10
• at P10 and at P18 - P22
• significant iron accumulation in splenic macrophages at P12
• at P18 - P22 spleen iron are increased 4.4-fold increase compared to controls

growth/size/body
• apparent within a few days of birth
• difference from controls becomes more prominent with age

homeostasis/metabolism
• significant iron accumulation in duodenal enterocytes at P12
• significant iron accumulation in splenic macrophages at P12
• at P18 - P22 spleen iron are increased 4.4-fold increase compared to controls
• significant iron accumulation in the Kupffer cells and hepatocytes at P12
• at P18 - P22 iron levels in the liver are reduced by 1.7-fold compared to controls

digestive/alimentary system
• significant iron accumulation in duodenal enterocytes at P12

immune system
• significant iron accumulation in splenic macrophages at P12
• at P18 - P22 spleen iron are increased 4.4-fold increase compared to controls

liver/biliary system
• significant iron accumulation in the Kupffer cells and hepatocytes at P12
• at P18 - P22 iron levels in the liver are reduced by 1.7-fold compared to controls

integument
• apparent within a few days of birth
• difference from controls becomes more prominent with age




Genotype
MGI:3771552
cn2
Allelic
Composition
Slc40a1tm2Nca/Slc40a1tm2Nca
Tg(Vil-cre)20Syr/0
Genetic
Background
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc40a1tm2Nca mutation (1 available); any Slc40a1 mutation (17 available)
Tg(Vil-cre)20Syr mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• no mice are found at birth due to recombination in the extraembryonic visceral endoderm




Genotype
MGI:3771553
cn3
Allelic
Composition
Slc40a1tm2Nca/Slc40a1tm2Nca
Tg(Vil-cre/ERT2)23Syr/0
Genetic
Background
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Slc40a1tm2Nca mutation (1 available); any Slc40a1 mutation (17 available)
Tg(Vil-cre/ERT2)23Syr mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• visibly anemic by 8 days after the first tamoxifen injection
• severe iron deficient anemia develops by 6 - 7 weeks after the start of tamoxifen treatment
• by 6 - 7 weeks after the start of tamoxifen treatment, average hematocrit is 11.2 +/- 1.6% compared to 45.3 +/- 5.9% in controls without the cre transgene
• parenteral treatment with iron dextran restores hematocrits in tamoxifen treated mice to levels similar to control mice that do not carry the cre transgene
• by 6 - 7 weeks after the start of tamoxifen treatment, average hemoglobin concentration is 2.8 +/- 0.6 g/dl compared to 13.8 +/- 1.8 g/dl in controls without the cre transgene
• a 4.7-fold decrease in splenic nonheme iron is seen after tamoxifen treatment

homeostasis/metabolism
• significant iron accumulation in duodenal enterocytes after tamoxifen treatment
• a 4.7-fold decrease in splenic nonheme iron is seen after tamoxifen treatment
• a 5.5-fold decrease in hepatic nonheme iron is seen after tamoxifen treatment

digestive/alimentary system
• significant iron accumulation in duodenal enterocytes after tamoxifen treatment

immune system
• a 4.7-fold decrease in splenic nonheme iron is seen after tamoxifen treatment

liver/biliary system
• a 5.5-fold decrease in hepatic nonheme iron is seen after tamoxifen treatment





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
06/22/2016
MGI 6.04
The Jackson Laboratory